Skip to content

The Clinical application of Combination of NADH and CoQ10 in patients with AIFM1 gene mutationpositive auditory neuropathy

The Clinical application of Combination of NADH and CoQ10 in patients with AIFM1 gene mutationpositive auditory neuropathy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096281
Enrollment
Unknown
Registered
2025-01-21
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Auditory Neuropathy

Interventions

case series:NADH(20-80mg/day) and CoQ10 (30-60mg/day)

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Meet the current international consensus criteria for the diagnosis of auditory neuropathy, i.e., the main clinical manifestations are that the patient can hear sounds but cannot understand their semantics, the patient's speech recognition rate is disproportionately reduced to the pure tone hearing threshold, the function of the hair cells is normal - Otoacoustic Emissions (OAE) and/or Cochlear Microphonics (CM) can be elicited, while abnormal auditory nerve function - Auditory Brainstem Responses (ABRs) are abnormal or completely absent; 2) AIFM1 gene mutation; 3) the age of onset of the disease is not limited to any age and gender (AIFM1 gene mutation-related auditory neuropathy is an X-linked genetic disorder, so it is prevalent in males). (AIFM1 gene mutation-associated auditory neuropathy is X-linked, so it is predominantly male), and the age of consultation is 14 years old or above; 4) patients and/or guardians voluntarily participate in this program and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1) pregnant, perinatal, and lactating women; 2) lesions such as middle ear lesions, Meniere's disease, acoustic neuroma, and greater vestibular aqueduct syndrome; 3) severe systemic diseases such as tumors, severe infections, cerebrovascular accidents, uremia, connective tissue disease, and acute stress; 4) cognitive disorders such as psychiatric disorders that interfere with adherence; 5) those who are poorly adherent to the regimen in the judgment of the investigator; 6) those who have had a unilateral or bilateral cochlear implantation; 7) patients who are deemed by the investigator to not be eligible for enrollment in this trial for other factors.

Design outcomes

Primary

MeasureTime frame
Hearing tests;

Secondary

MeasureTime frame
vestibular function tests;laboratory tests;imaging tests;

Countries

China

Contacts

Public ContactWang Qiuju

Chinese PLA General Hospital

wqcr301@vip.sina.com+86 10 5549 9143

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026